Fig. 2.

Achievement of DAPSA remission, cDAPSA remission, PASDAS VLDA, and VLDA

(A) DAPSA remission; (B) cDAPSA remission; (C) PASDAS VLDA; (D) VLDA. Through week 24, patients meeting treatment failure criteria or with missing data were considered non-responders. Treatment group comparisons through week 24 were not adjusted for multiplicity of testing. After week 24 and through week 52, patients with missing data were considered non-responders. *P < 0.05, ⁺P < 0.01, ^‡P < 0.001, vs PBO (nominal). cDAPSA: clinical DAPSA (excludes CRP); DAPSA: Disease Activity in Psoriatic Arthritis; GUS: guselkumab; PASDAS: Psoriatic Arthritis Disease Activity Score; PBO: placebo; Q4W: every 4 weeks; Q8W: every 8 weeks; VLDA: very low disease activity.